The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -43,774 | 42,526 | -117,809 | -25,863 |
| Imputed interest - related parties | 3,503 | 3,129 | 2,710 | 3,315 |
| Liability forgiveness | - | 62,032 | - | - |
| Security deposit | - | 2,315 | 2,285 | - |
| Liability extinguishment | -20,000 | - | - | - |
| Prepaid expenses | -10,000 | 10,000 | -35,000 | 35,000 |
| Operating lease liability | 0 | - | - | - |
| Accounts payable and accrued expenses | 450 | -1,315 | 23,404 | -58,967 |
| Net cash used in operating activities | -49,821 | -25,377 | -54,410 | -116,515 |
| Advances from related parties | 49,596 | 25,152 | 58,707 | 116,065 |
| Net cash provided by financing activities | 49,596 | 25,152 | 58,707 | 116,065 |
| Net change in cash | -225 | -225 | 4,297 | -450 |
| Cash at beginning of period | 4,098 | 4,323 | 476 | - |
| Cash at end of period | 3,873 | 4,098 | 4,323 | - |
ACRO BIOMEDICAL CO., LTD. (ACBM)
ACRO BIOMEDICAL CO., LTD. (ACBM)